Overview

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter trial to evaluate the impact of treatment with dapagliflozin versus placebo following catheter ablation of atrial fibrillation (AF) on the burden of AF during 12 months of follow-up. This prospective, randomized, multicenter, placebo-controlled trial aims to enroll 100 subjects with AF (paroxysmal or persistent) who are scheduled to undergo catheter ablation of patients.

Phase:

Phase 4

Details

Lead Sponsor:

University of Rochester

Collaborator:

AstraZeneca

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin